Literature DB >> 11906771

Immune response to synthetic peptides of dengue prM protein.

Susana Vázquez1, María Guadalupe Guzmán, Gerardo Guillen, Glay Chinea, Ana Beatriz Pérez, Maritza Pupo, Rosmary Rodriguez, Osvaldo Reyes, Hilda Elisa Garay, Iselys Delgado, Gissel García, Mayling Alvarez.   

Abstract

The immunological activities of five synthetic peptides of the prM protein of dengue-2 (DEN-2) virus containing B cell epitopes were evaluated in BALB/c mice. Two peptides elicited neutralizing antibodies against all four DEN serotypes. Virus-specific proliferative responses were demonstrated in mice immunized with four of the five peptides, demonstrating the presence of T cell epitopes. Mice immunized with three of the five peptides conjugated with bovine albumin showed statistically significant levels (P<0.05) of protection when challenged with DEN-2 virus. These results could constitute the basis for the establishment of the role of DEN virus pre and M antigens in the development of anti-flaviviral vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906771     DOI: 10.1016/s0264-410x(01)00515-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

Review 1.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals.

Authors:  Joseph D Comber; Aykan Karabudak; Xiaofang Huang; Paolo A Piazza; Ernesto T A Marques; Ramila Philip
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

Review 4.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

Review 5.  Degrees of maturity: the complex structure and biology of flaviviruses.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2012-03-23       Impact factor: 7.090

6.  Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response.

Authors:  James S Testa; Vivekananda Shetty; Gomathinayagam Sinnathamby; Zacharie Nickens; Julie Hafner; Shivali Kamal; Xianchao Zhang; Marti Jett; Ramila Philip
Journal:  J Infect Dis       Date:  2012-01-13       Impact factor: 5.226

7.  Optimized Expression of Duck Tembusu Virus E Gene Delivered by a Vectored Duck Enteritis Virus In Vitro.

Authors:  Liu Chen; Bin Yu; Jonggang Hua; Zheng Ni; Weicheng Ye; Tao Yun; Cun Zhang
Journal:  Mol Biotechnol       Date:  2019-10       Impact factor: 2.695

8.  The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection.

Authors:  Theodore C Pierson; Qing Xu; Steevenson Nelson; Theodore Oliphant; Grant E Nybakken; Daved H Fremont; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-04-19       Impact factor: 21.023

9.  Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.

Authors:  W M P B Wahala; Annette A Kraus; Laura B Haymore; Mary Ann Accavitti-Loper; Aravinda M de Silva
Journal:  Virology       Date:  2009-07-24       Impact factor: 3.616

10.  Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Whitney E Purtha; Theodore Oliphant; Grant E Nybakken; Jacob J Schlesinger; John T Roehrig; Gregory D Gromowski; Alan D Barrett; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.